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Cushing’s disease (CD) in children is caused by adrenocorticotropic hormone  
(ACTH)-secreting pituitary adenomas. Germline or somatic mutations in genes such 
as MEN1, CDKIs, AIP, and USP8 have been identified in pediatric CD, but the genetic 
defects in a significant percentage of cases are still unknown. In this study, we 
investigated the orphan G-protein-coupled receptor GPR101, a gene known to be 
involved in somatotropinomas, for its possible involvement in corticotropinomas. We 
performed GPR101 sequencing, expression analyses by RT-qPCR and immunostaining, 
and functional studies (cell proliferation, pituitary hormone secretion, and cAMP 
measurement) in a series of patients with sporadic CD secondary to ACTH-secreting 
adenomas in whom we extracted DNA from peripheral blood and pituitary tumor 
samples (n = 36). No increased GPR101 expression was observed in tumors compared 
with normal pituitary (NP) tissues, nor did we find a correlation between GPR101 and 
ACTH expression levels. Sequence analysis revealed a very rare germline heterozygous 
GPR101 variant (p.G31S) in one patient with CD. Overexpression of the p.G31S variant 
did not lead to increased growth and proliferation, although modest effects on cAMP 
signaling were observed. GPR101 is not overexpressed in ACTH-secreting tumors 
compared with NPs. In conclusion, rare germline GPR101 variant was found in one 
patient with CD, but in vitro studies did not support a consistent pathogenic effect. 
GPR101 is unlikely to be involved in the pathogenesis of CD.
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Introduction
Cushing’s disease (CD) affects approximately 70% of 
patients with endogenous Cushing’s syndrome (Tritos & 
Biller 2014). CD is caused by adrenocorticotropic hormone 
(ACTH)-secreting pituitary adenomas (corticotropinomas) 
(Newell-Price 2009). Although germline mutations 
in genes such as MEN1, CDKIs, and AIP, and somatic 
mutations in USP8 have been identified in patients with 
CD, for many corticotropinomas the molecular pathways 
involved in their pathogenesis remain unknown (Stratakis 
et al. 2010, Reincke et al. 2015).
We have recently found that the GPR101 gene is 
involved in the pathogenesis of pituitary growth hormone 
(GH)-secreting adenomas (Trivellin et  al. 2014, Beckers 
et al. 2015). GPR101 encodes an orphan G protein-coupled 
receptor that is highly expressed in the hypothalamus, 
where it may play a role in the hypothalamic control 
of energy homeostasis and pituitary hormone secretion 
(Lee et al. 2001, Bates et al. 2006, Nilaweera et al. 2007, 
2008, Regard et  al. 2008, Trivellin et  al. 2014). GPR101 
is also highly expressed in the GH-secreting pituitary 
tumors of patients with X-linked acrogigantism caused 
by GPR101 duplication, whereas it is expressed at low 
levels in normal pituitary (NP) tissue and in non-GPR101 
duplicated somatotropinomas (Trivellin et al. 2014). The 
mechanism(s) by which GPR101 might increase pituitary 
hormones secretion remain unclear at present, although 
the possible involvement of GHRH has been shown 
(Beckers et al. 2015, Daly et al. 2016). Previous studies from 
our and other groups support the idea that GPR101 can 
strongly activate the cAMP pathway (Trivellin et al. 2014, 
Bates et  al. 2006), whose mitogenic effects in pituitary 
cells are well established (Peverelli et al. 2014).
In this study, we investigated the possible involvement 
of GPR101 in CD by performing GPR101 sequencing, 
expression analyses, and functional studies in a series of 
sporadic ACTH-secreting adenomas. We further report a 
case associated with a very rare missense variant (p.G31S).
Subjects and methods
Subjects
A series of 36 patients with CD corroborated by 
biochemical testing and pathology positive for ACTH 
staining in pituitary adenomas were analyzed. These 
patients were selected because of the availability of 
tumor and peripheral DNA samples. Testing for germline 
mutations/deletions in genes associated with pituitary 
adenomas (AIP, MEN1) was performed and no defects 
were observed. Patients harboring a USP8 mutation at the 
tumor DNA level were also excluded from this analysis 
(data not shown). The Eunice Kennedy Shriver National 
Institute of Child Health and Human Development 
Institutional Review Board approved this study, and 
informed consent was obtained from all the patients.
Sequencing analysis
DNA was extracted from peripheral blood and pituitary 
tumor samples using the QIAamp DNA Mini Kit (Qiagen) 
according to the manufacturer’s protocols. The whole 
coding region of GPR101 was PCR amplified and directly 
sequenced. The following primers were used: GPR101_1AF: 
ACTGAGCCTGCAACCTGTCT; GPR101_1AR: TCCACTG 
ACACCACGACAAT; GPR101_1BF: TTAGCCTCACCCAC 
CTGTTC; GPR101_1BR: CTTCCTTCCTTGGCCTTCAG; 
GPR101_1CF: CAGCATGAAGGTGAGGTCAA; GPR101_ 
1CR: CCCAGGGATAGCACATAGGA; GPR101_1DF: GTGC 
TACCAGTGCAAAGCTG; GPR101_1DR: TGAATTGTGGG 
TCCATTGAA. DNA sequencing was performed using the 
BigDye 3.1 termination chemistry (Applied Biosystems) 
on a Genetic Sequencer ABI 3500XL apparatus (Applied 
Biosystems). Sequences were visualized and aligned to the 
corresponding wild-type (WT) reference sequence using 
SeqMan Pro software (DNASTAR, Madison, Wisconsin, 
USA). All variants have been annotated according to 
Human Genome Variation Society recommendations 
(www.hgvs.org/mutnomen). The NM_054021.1 reference 
sequence was used to annotate GPR101 variants.
Figure 1
DNA sequence chromatograms showing the position of two GPR101 
variants found in our patients. The homozygous p.T293I variant is shown 
on the left side, whereas the heterozygous p.G31S variant on the right 
side. The location of each nucleotide change is indicated by a red arrow. 
Below each chromatogram, the WT nucleotide sequence and the 
corresponding codon numbers are reported.
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In silico analysis
All GPR101 variants were studied in silico, and the 
allele frequencies observed in our patient population 
were compared against public databases, including the 
1000 Genomes Project (Auton et  al. 2015); the Exome 
Variant Server, NHLBI GO Exome Sequencing Project, 
Seattle, Washington, USA (http://evs.gs.washington.
edu/EVS/) (accessed February 2016); and the Exome 
Aggregation Consortium, Cambridge, MA, USA (http://
exac.broadinstitute.org) (accessed February 2016). In silico 
predictions were performed with PON-P2 (Niroula et  al. 
2015) and Alamut version 2.3 (Interactive Biosoftware, 
Rouen, France) software packages.
Tissue collection and expression studies
Pituitary tumor tissue was collected at surgery. Whenever 
possible, tissue slices were snap-frozen in dry ice; the 
remainder was fixed in formalin and embedded in 
paraffin. Five-micrometer-thick sections were stained 
with hematoxylin–eosin and reticulin for light 
microscopy. The avidin–biotin peroxidase complex 
technique was used to stain for ACTH using an anti-
ACTH rabbit polyclonal antibody (Dako; catalog no. 
A0571) at a working dilution of 1:1000. Some samples 
were also stained in immunofluorescence for GPR101 
(rabbit anti-GPR101, dilution 1:500; SAB4503289, Sigma-
Aldrich) and ACTH (rabbit anti-ACTH, dilution 1:400, Dr 
A F Parlow, National Institute of Diabetes and Digestive 
and Kidney Diseases, National Hormone and Peptide 
Program, Torrance, CA, USA). Immunofluorescence 
staining for GPR101 was performed using a Tyramide 
signal amplification kit (T20922, Invitrogen) with a 
horseradish peroxidase-goat anti-rabbit IgG and Alexa 
fluor 488 tyramide, according to the manufacturer’s 
instructions. The sections were mounted in Mowiol and 
visualized under a Leica AF6000 microscope (Leica) at 63× 
magnification with fixed time of exposure for all samples. 
The same linear adjustments for brightness, contrast, and 
color balance have been applied with Adobe Photoshop 
CS6 to each entire image.
GPR101 and POMC mRNA expression levels 
were measured by RT-qPCR with TaqMan assay IDs 
Hs00369662_s1 and Hs01596743_m1, respectively (Applied 
Biosystems) and normalized on GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) expression (TaqMan assay 
ID Hs99999905_m1, Applied Biosystems). TaqMan assays 
were performed according to the manufacturer’s protocol 









































































































































































































































































































































































































































































































































































































































































http://erc.endocrinology-journals.org © 2016 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
23:5
in 96-microwell plates and consisted of 20 µL reactions 
containing 20 ng of cDNA, 10 µL TaqMan Gene Expression 
Master Mix (Applied Biosystems, catalog number 4369016), 
and 1 µL each of GPR101 and GAPDH assay mixes. All 
reactions were performed in triplicate and were run on a 
ViiA 7 Real-Time PCR System (Applied Biosystems). Thermal 
cycling conditions were 95°C, 10 min followed by 40 cycles 
of 95°C for 15 s, and 60°C for 1 min. Relative gene expression 
data were analyzed by ΔΔCt method. Data analysis was 
performed using ViiA 7 software (Applied Biosystems).
Plasmids
The human GPR101 WT (NM_054021.1) coding sequence 
cloned into the pCMV-XL5 vector was purchased from 
Origene (SC120214, Origene, Rockville, MD, USA). The 
p.G31S variant was introduced into the human GPR101 
WT template using the QuikChange Lightning Site-
directed Mutagenesis Kit (210518-5, Agilent Technologies), 
following the manufacturer’s protocol. The  following 




The rat pituitary somatomammotroph GH3 cell line 
and the mouse pituitary corticotroph AtT-20 cell line 
were grown in Dulbecco’s modified Eagle’s medium 
(DMEM, high glucose, pyruvate, no glutamine; 10313, 
Gibco) supplemented with 10% fetal bovine serum (100-
106, Gemini Bio Products, West Sacramento, CA, USA) 
and 1% antibiotic–antimycotic (15240-062, Gibco) in a 
humidified atmosphere at 37°C with 5% CO2.
Cell proliferation assay
GH3 cells were seeded into 96-well plates at a density of 
2 × 104 cells per well. After 24 h, cells were starved with 
DMEM without serum for 16 h and then transfected with 
Lipofectamine 2000 (11668030, Invitrogen) according to 
the manufacturer’s protocol, using Opti-MEM I Reduced 
Serum Medium (31985-070, Gibco) and 125 ng of each 
vector (human WT GPR101, p.G31S GPR101), alone or in 
combination. The empty pCMV-XL5 vector was used as a 
negative control.
AtT-20 cells were plated and transfected following 
the same protocol, but were not starved, because we 
Figure 2
GPR101 and POMC mRNA expression levels in 
corticotropinomas. None of the analyzed samples 
harbored GPR101 defects. (A and B) A trend 
toward higher GPR101 expression in ACTH-
secreting tumors can be seen, but it does not 
reach statistical significance (P = 0.14). (C) No 
correlation between GPR101 and POMC 
expression levels was observed in ACTH-secreting 
tumors (Spearman’s R = 0.08, P = 0.83). Data are 
expressed as mean ± s.d. *P < 0.05. NPA, anterior 
lobe of normal pituitary; NPP, posterior lobe of 
normal pituitary; ACTH, ACTH-secreting tumor.
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observed that starvation significantly impacts cell 
viability. After 24 h transfection, cell viability and cellular 
proliferation were assessed for both cell lines with an MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide)-based assay (Vybrant MTT Cell Proliferation 
Assay Kit, Invitrogen) as described previously (Trivellin 
et al. 2014).
cAMP reporter assay
GH3 and AtT-20 cells were seeded in 12-well plates at a 
density of 2 × 105 cells per well. After 24 h, GH3 cells only 
were starved with DMEM without serum for 16 h, and 
then both cell lines were transfected with Lipofectamine 
2000 according to the manufacturer’s protocol, using 
Opti-MEM I Reduced Serum Medium, 1 μg of each GPR101 
vector (human WT GPR101, p.G31S GPR101), 800 ng of 
pGL4.29[luc2P/CRE/Hygro] vector containing a cAMP 
response element that drives the transcription of the 
luciferase reporter gene (Promega), and 40 ng of the Renilla 
vector (pRL-SV40, Promega). The empty pCMV-XL5 vector 
was used as a negative control. At 24 h after transfection, 
a subset of cells was treated with 10 βM forskolin (F6886, 
Sigma-Aldrich) for 1 h and then lysed. Firefly and Renilla 
luciferase activities were measured consecutively in the 
same sample using the Dual-Luciferase Reporter Assay 
System (E1910, Promega) as described previously (Trivellin 
et al. 2014).
Hormone assays
GH3 and AtT-20 cells were seeded in 12-well plates and 
then transfected as reported in the ‘cAMP reporter assay’ 
section, using 1 μg of each GPR101 vector. At 24 h after 
transfection, supernatants were collected and hormone 
concentration was measured. For GH3 cells, GH secretion 
was measured using the rat/mouse Growth Hormone 
ELISA Kit (EZRMGH-45K, EMD Millipore) as described 
previously (Trivellin et al. 2014). For AtT-20 cells, ACTH 
secretion was measured using the ACTH (rat, mouse) 
Chemiluminescent EIA KIT (CEK-001-21, Phoenix 
Pharmaceuticals, Belmont, CA, USA) following the 
manufacturer’s protocol.
Statistical analyses
Statistical analysis was performed using StatsDirect 
software (Addison-Wesley-Longman, Cambridge, UK). 
Data are presented as the mean ± s.d. of two to five 
independent experiments, each performed at least in 
triplicate. Comparisons were calculated using a two-tailed 
Student’s t-test for unpaired data and the Kruskal–Wallis 
test followed by the Conover–Inman test, as appropriate. 
A χ2-test was used to compare the allelic frequencies of the 
variants in patients and controls. Spearman’s correlation 
coefficient by rank was used to compare GPR101 and 
POMC mRNA expression levels. The data were considered 
to be significant when P < 0.05.
Figure 3
ACTH immunostaining in corticotroph tumors of 
four patients with CD. ACTH protein expression 
(red) of cases ACTH_7, 8, and 9 reflects the POMC 
mRNA levels shown in Fig. 2C. The tumor of the 
patient harboring the p.G31S GPR101 variant 
shows some ACTH-positive sparse cells, as also 
shown in Fig. 4D.
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Results
GPR101 sequencing analysis in ACTH-secreting tumors
Germline DNA from 36 patients with CD (58% females, 
mean age at diagnosis: 14.4 ± 8.13 years old) was sequenced 
for GPR101; 32 of these patients have been included in our 
previous series of pediatric patients with CD (Stratakis et al. 
2010, Trivellin et  al. 2014). Two common SNPs (p.V124L 
and p.L376P) were detected in several patients’ samples 
with frequencies comparable to those observed in control 
subjects, similarly to what we previously reported (Trivellin 
et  al. 2014), and a less common SNP (p.T293I, 5% allele 
frequency in controls) was observed in one patient in the 
homozygote state (Fig. 1). In silico analysis was not supportive 
for pathogenic function (Table 1). A very rare variant (p.G31S) 
was detected in another patient in the heterozygote state. 
Although some in silico programs reported it as benign, others 
classified it as possibly damaging (Table 1). These patients had 
classic CD without atypical features (Supplementary Table 1, 
see section on supplementary data given at the end of this 
article). GPR101 sequencing was also performed successfully 
at the somatic level in 33 ACTH-secreting tumors; no de novo 
somatic variants were reported in GPR101.
GPR101–ACTH expression in ACTH-secreting tumors
We performed RT-qPCR for GPR101 in 10 cortico-
tropinomas and 3 NPs collected at autopsy. Each NP was 
divided into the anterior and posterior lobes. None of 
these samples harbored GPR101 mutations. We observed 
a trend toward higher GPR101 expression in the tumors 
compared with NPs, with this being particularly evident 
for three samples (Fig. 2A), but it did not reach statistical 
significance (P = 0.14, Fig. 2B).
We then measured POMC mRNA expression in the 
tumor samples to determine if there was a correlation with 
GPR101 mRNA levels. We found no correlation between 
GPR101 and POMC expression levels (Spearman’s R = 0.08, 
P = 0.83, Fig. 2C). ACTH expression in four available tumors 
was also investigated at the protein level by immunostaining 
(Fig. 3). ACTH protein expression corresponded well with 
POMC mRNA levels as shown in Fig. 2C. ACTH expression 
levels in the patient harboring the p.G31S GPR101 variant 
were intermediate between those of the other three analyzed 
tumors; in the patient with the homozygous p.T293I variant 
it was unremarkable (Figs  3 and 4). GPR101 staining was 
performed in the same specimens but resulted in nonspecific 
signal that could be a consequence of tissue collection/
preparation (data not shown). We had successful double 
labeling with two antibodies raised in rabbit (including 
GPR101), but it just did not work with these tumor samples.
In vitro functional studies for GPR101 p.G31S variant
Based on the in silico results and on the very low allele 
frequency with which the p.G31S variant is reported in 
Figure 4
Imaging and histopathological findings for 
patients with GPR101 variants. Patient with the 
p.T293I GPR101 variant in homozygosity: (A) 
There is a round space-occupying lesion in the 
right half of the pituitary showing decrease 
enhancement with respect to NP tissue. This 
abnormality represents the microadenoma that 
abuts the intracavernous segment of the right 
internal carotid artery. The bony defect inferior 
to the adenoma is the result of a prior surgery. 
(B) ACTH staining of the microadenoma showing 
diffuse and strong ACTH expression. Patient with 
the heterozygous p.G31S GPR101 variant: (C) 
Reticulin staining showing disruption of reticulin 
network and expanded hyperplastic acini. (D) 
ACTH staining showing an expression pattern 
typical of normal anterior pituitary. All three 
images were taken at 10× magnification.
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the population (making it more likely to be pathogenic), 
we performed in vitro functional studies. An MTT assay 
was performed in AtT-20 and GH3 cells, but no effect of 
the variant was observed on cell proliferation in neither 
cell lines (Fig. 5A and B). Moreover, overexpression of the 
WT GPR101 construct did not increase cell proliferation 
in either cell lines, as previously observed (Trivellin et al. 
2014). ACTH and GH secretion from, respectively, AtT-
20 and GH3 cells was also measured after overexpression 
of the p.G31S variant. No increased secretion of either 
hormones was observed compared with cells transfected 
with mock control, neither for WT nor for mutated 
p.G31S GPR101 (Fig. 5C and D). Activation of the 
cAMP pathway was measured with a reporter assay in 
AtT-20 and GH3 cells upon p.G31S overexpression. In 
both cell lines, a significant increase in cAMP levels 
was observed compared with mock control (P < 0.001); 
however, this increase was not different from what was 
seen with the WT GPR101 construct (Fig. 5E and F). In 
basal conditions, the increase in cAMP activation caused 
by GPR101 overexpression in AtT-20 cells (Fig. 5E) was 
lower than that seen in GH3 cells (P < 0.001, Fig. 5F). 
The additional stimulation of the cAMP pathway with 
forskolin showed a synergistic effect only in AtT-20 cells 
(Fig. 5E and F).
Discussion
GPR101 has been previously shown to be expressed in 
hypothalamic neurons expressing proopiomelanocortin 
(POMC), the precursor of ACTH (Nilaweera et  al. 2007, 
Bagnol 2010). Moreover, GPR101 was shown to mediate 
the phosphorylation of epidermal growth factor receptor 
(EGFR), leading to enhanced cellular migration (Cho-Clark 
et  al. 2014) and invasion (Cho-Clark et  al. 2015). EGFR 
is frequently overexpressed in ACTH-secreting tumors, 
and the EGFR-mediated pathway is essential for POMC 
synthesis (Theodoropoulou et  al. 2004, Fukuoka et  al. 
2011). A GPR101 variant, p.E308D, previously observed 
in some patients with GH-secreting adenomas (Trivellin 
et al. 2014) was also recently reported in two patients with 
ACTH-secreting adenomas (Lecoq et al. 2016).
Based on the possible link between GPR101 and 
the physiology of ACTH-secreting cells, we decided 
Figure 5
In vitro functional studies in pituitary tumor cell 
lines. An MTT assay was performed in AtT-20 (A) 
and GH3 cells (B). No effect of the WT GPR101 
nor of the p.G31S variant was observed on cell 
proliferation. Mouse ACTH (C) and rat GH (D) 
secretion was measured with specific ELISA assays 
from AtT-20 and GH3 cell supernatants, 
respectively. No effect of the WT GPR101 nor of 
the p.G31S variant was observed on the secretion 
of both hormones. cAMP pathway activation was 
measured in AtT-20 (E) and GH3 (F) cells upon 
GPR101 overexpression. A significant increase in 
cAMP levels was observed in both cell lines 
compared with control, but this increase was not 
different between WT and mutated GPR101. 
Data are expressed as mean ± s.d. of two to three 
independent experiments, each performed in 
triplicate. *P < 0.05; ***P < 0.001.
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to study if GPR101 plays a role in the pathogenesis of 
corticotropinomas. As nothing is known regarding 
the expression of the receptor in these tumors, we first 
measured its expression levels in 10 corticotropinomas 
and compared them with three NP samples. We did not 
observe different expression levels of GPR101 between 
tumors and NP tissues (Fig. 2A and B). Moreover, no 
correlation with POMC expression levels was observed 
(Fig. 2C). We then sequenced a series of patients with 
CD to look for possible GPR101 germline and somatic 
mutations. In addition to two very common SNPs, two 
other missense variants (p.G31S and p.T293I) were 
observed at the germline level (Fig. 1). Both variants 
have been reported in public databases and in the 
literature (Trivellin et  al. 2014, Castinetti et  al. 2016). 
Although p.T293I is a relatively common variant with a 
minor allele frequency (MAF) of about 6% (an average 
calculated from three public databases, Table 1), p.G31S 
is a very rare variant, with a MAF of about 0.06%, and 
was predicted in silico to be possibly damaging. However, 
functional in vitro studies of this variant did not show an 
increase in hormone secretion nor in cell proliferation 
(Fig. 5). We were able to see a significant increase in cAMP 
pathway activation, compared with controls, but this was 
not significantly different from that elicited by the WT 
GPR101 construct (Fig. 5E and F). It is also interesting 
to note that in basal conditions, the increase in cAMP 
pathway activation caused by GPR101 overexpression 
in AtT-20 cells (Fig.  5E) was significantly lower than 
that seen in GH3 cells (Fig.  5F; Trivellin et  al. 2014). 
Only in the presence of a potent stimulator of the cAMP 
pathway, GPR101 was able to exert on the AtT-20 cells 
an effect of similar magnitude to that observed in GH3 
cells. These findings suggest that GPR101 may activate 
the cAMP pathway at different magnitudes in different 
hormone-secreting cell types. The lower activation of 
the cAMP pathway in corticotrophs might be in line 
with some studies, indicating that this pathway does not 
play a significant pathogenetic role in corticotropinomas 
(reviewed in (Bertagna 2011)). Therefore, it might be 
possible that GPR101 activates different intracellular 
signaling pathways in corticotroph cells than in 
somatotrophs. It would be interesting to investigate this 
aspect in future studies, in particular in relation to the 
p.G31S variant.
In conclusion, in this study we investigated pediatric 
patients with CD for GPR101 defects but found little 
to support that this gene might be involved in the 
pathogenesis of corticotropinomas. The finding of a rare, 
potentially functional GPR101 variant in one patient with 
CD was interesting, but in vitro studies did not support a 
tumor-inducing role for this sequence change.
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